SIMPLIFY-2: Momelotinib vs Best Available Therapy in Ruxolitinib-Experienced Pts With Myelofibrosis

Source: 2017 American Society of Clinical Oncology Annual Meeting*
Download Slideset
June 2-6, 2017; Chicago, Illinois
Results from this phase III study reveal comparable splenic response rate but improved symptomatic response and transfusion independence rates with momelotinib vs BAT.
Format: Microsoft PowerPoint (.ppt)
File Size: 949 KB
Released: June 9, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings